EGFR and metastatic colorectal cancer: Their pan-αv blocking humanised antibody Abituzumab was compared with the standard of care (cetuximab, an EGFR inhibitor and irinotecan, a topoisomerase 1 inhibitor) in metastatic colorectal cancer (CRC; Elez et al. 2015).